Myriad Genetics, Inc. (NASDAQ:MYGN) insider Alexander Ford sold 3,031 shares of the firm’s stock in a transaction that occurred on Monday, November 13th. The shares were sold at an average price of $31.64, for a total value of $95,900.84. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.
Shares of Myriad Genetics, Inc. (NASDAQ:MYGN) traded down $0.11 on Thursday, hitting $31.25. The stock had a trading volume of 1,062,500 shares, compared to its average volume of 1,220,785. Myriad Genetics, Inc. has a one year low of $15.15 and a one year high of $37.30. The company has a debt-to-equity ratio of 0.09, a quick ratio of 2.06 and a current ratio of 2.34. The company has a market cap of $2,171.39, a price-to-earnings ratio of 28.77, a price-to-earnings-growth ratio of 1.99 and a beta of 0.24.
Myriad Genetics (NASDAQ:MYGN) last issued its quarterly earnings results on Tuesday, November 7th. The company reported $0.26 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.21 by $0.05. Myriad Genetics had a return on equity of 9.54% and a net margin of 13.28%. The company had revenue of $190.20 million for the quarter, compared to analyst estimates of $183.52 million. During the same quarter last year, the company posted $0.23 EPS. The company’s revenue for the quarter was up 7.2% compared to the same quarter last year. equities analysts expect that Myriad Genetics, Inc. will post 1.05 earnings per share for the current fiscal year.
A number of research firms have recently issued reports on MYGN. Zacks Investment Research raised Myriad Genetics from a “hold” rating to a “strong-buy” rating and set a $42.00 price objective for the company in a research report on Tuesday, October 17th. Jefferies Group LLC reaffirmed a “hold” rating and issued a $23.00 price objective (up from $21.00) on shares of Myriad Genetics in a research report on Thursday, August 10th. Cowen and Company reaffirmed a “hold” rating and issued a $25.00 price objective on shares of Myriad Genetics in a research report on Sunday, September 17th. Deutsche Bank AG raised Myriad Genetics from a “sell” rating to a “hold” rating and cut their price objective for the company from $27.86 to $15.00 in a research report on Friday, August 18th. Finally, Stephens reaffirmed an “overweight” rating and issued a $40.00 price objective (up from $36.00) on shares of Myriad Genetics in a research report on Friday, September 22nd. Two analysts have rated the stock with a sell rating, seven have issued a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus price target of $28.10.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. UBS Asset Management Americas Inc. lifted its holdings in Myriad Genetics by 45.0% during the 1st quarter. UBS Asset Management Americas Inc. now owns 34,364 shares of the company’s stock worth $660,000 after buying an additional 10,667 shares during the period. FMR LLC lifted its holdings in Myriad Genetics by 1.5% during the 1st quarter. FMR LLC now owns 403,900 shares of the company’s stock worth $7,755,000 after buying an additional 5,900 shares during the period. Teachers Advisors LLC lifted its holdings in Myriad Genetics by 1.1% during the 1st quarter. Teachers Advisors LLC now owns 116,924 shares of the company’s stock worth $2,245,000 after buying an additional 1,287 shares during the period. Vanguard Group Inc. lifted its holdings in Myriad Genetics by 16.8% during the 1st quarter. Vanguard Group Inc. now owns 6,251,030 shares of the company’s stock worth $120,020,000 after buying an additional 897,287 shares during the period. Finally, Geode Capital Management LLC lifted its holdings in Myriad Genetics by 3.0% during the 1st quarter. Geode Capital Management LLC now owns 661,307 shares of the company’s stock worth $12,696,000 after buying an additional 19,251 shares during the period.
About Myriad Genetics
Myriad Genetics, Inc is a molecular diagnostic company. The Company is engaged in the discovery, development and marketing of transformative molecular diagnostic tests. The Company operates through two segments: diagnostics and other. The diagnostics segment provides testing and collaborative development of testing that is designed to assess an individual’s risk for developing disease later in life, identify a patient’s likelihood of responding to drug therapy and guide a patient’s dosing to enable optimal treatment, or assess a patient’s risk of disease progression and disease recurrence.
Receive News & Ratings for Myriad Genetics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.